Latest statistics and disclosures from Omega Fund Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NUVB, REPL, IMGO, MORF, KRON, and represent 68.37% of Omega Fund Management's stock portfolio.
- Added to shares of these 2 stocks: Cincor Pharma (+$17M), THRX (+$8.2M).
- Started 2 new stock positions in THRX, Cincor Pharma.
- Reduced shares in these 10 stocks: NUVB (-$28M), ADGI (-$27M), AVIR (-$5.8M), MORF, CDTX, REPL, OBSV, PRTK, TRVI, GOSS.
- Sold out of its positions in ADGI, AVIR, CDTX, FGEN, TRVI, OBSV.
- Omega Fund Management was a net seller of stock by $-57M.
- Omega Fund Management has $489M in assets under management (AUM), dropping by -45.18%.
- Central Index Key (CIK): 0001637359
Tip: Access up to 7 years of quarterly data
Positions held by Omega Fund Management consolidated in one spreadsheet with up to 7 years of dataDownload as csv Download as Excel
Portfolio Holdings for Omega Fund Management
Companies in the Omega Fund Management portfolio as of the March 2022 quarterly 13F filing
|Company (Ticker)||Portfolio Weight||Valued At||Change in Shares||Share Count||Share Price|
|Nuvation Bio Class A Common Stock (NUVB)||24.7||$121M||-18%||23M||5.26|
|Replimune Group Common Stock (REPL)||16.2||$79M||-4%||4.7M||16.98|
|Imago Biosciences Common Stock (IMGO)||11.9||$58M||3.0M||19.27|
|Morphic Holding Common Stock (MORF)||9.9||$48M||-8%||1.2M||40.15|
|Kronos Bio Common Stock (KRON)||5.6||$28M||3.8M||7.23|
|Gossamer Bio Common Stock (GOSS)||5.6||$28M||-4%||3.2M||8.68|
|Immunic Common Stock (IMUX)||4.1||$20M||1.8M||11.30|
|Alpine Immune Sciences Common Stock (ALPN)||3.7||$18M||2.0M||8.97|
|Cincor Common Stock||3.5||$17M||NEW||966k||17.54|
|Ikena Oncology Common Stock (IKNA)||2.8||$14M||2.2M||6.10|
|Arcutis Biothereapeutics Common Stock (ARQT)||2.5||$12M||624k||19.26|
|Theseus Pharmaceuticals Common Stock (THRX)||1.7||$8.2M||NEW||712k||11.53|
|Sana Biotechnology Common Stock (SANA)||1.4||$7.0M||844k||8.26|
|Paratek Pharmaceuticals Common Stock (PRTK)||1.2||$5.9M||-24%||2.0M||2.97|
Setup an alert
Omega Fund Management will file the next quarterly 13-HR in about 3 months. Would you like to be notified?
|Omega Alpha SPAC Class A Common Stock (OMEG)||1.0||$4.9M||501k||9.82|
|Spruce Biosciences Common Stock (SPRB)||0.9||$4.3M||2.2M||2.01|
|Checkmate Pharmaceuticals Common Stock (CMPI)||0.9||$4.3M||1.3M||3.19|
|Icosavax Common Stock (ICVX)||0.6||$3.0M||426k||7.04|
|Syros Pharmaceuticals Common Stock (SYRS)||0.6||$3.0M||2.5M||1.19|
|ESSA Pharma Common Stock (EPIX)||0.4||$2.0M||328k||6.18|
|Jounce Therapeutics Common Stock (JNCE)||0.4||$1.9M||276k||6.79|
|Immunocore Holdings Common Stock (IMCR)||0.3||$1.5M||52k||29.90|
Past Filings by Omega Fund Management
SEC 13F filings are viewable for Omega Fund Management going back to 2014
- Omega Fund Management 2022 Q1 filed May 13, 2022
- Omega Fund Management 2021 Q3 filed Nov. 15, 2021
- Omega Fund Management 2021 Q1 amended filed Nov. 15, 2021
- Omega Fund Management 2021 Q2 amended filed Nov. 15, 2021
- Omega Fund Management 2021 Q2 filed Aug. 16, 2021
- Omega Fund Management 2021 Q1 filed May 17, 2021
- Omega Fund Management 2020 Q4 filed Feb. 16, 2021
- Omega Fund Management 2020 Q3 filed Nov. 16, 2020
- Omega Fund Management 2020 Q2 filed Aug. 17, 2020
- Omega Fund Management 2020 Q1 filed May 14, 2020
- Omega Fund Management 2019 Q4 filed Feb. 13, 2020
- Omega Fund Management 2019 Q3 filed Nov. 13, 2019
- Omega Fund Management 2019 Q2 filed Aug. 13, 2019
- Omega Fund Management 2019 Q1 amended filed May 20, 2019
- Omega Fund Management 2019 Q1 filed May 15, 2019
- Omega Fund Management 2018 Q4 filed Feb. 11, 2019